Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 106

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 106
---
, promotion and sale of their tests than we do, sell their tests at prices designed to win significant levels of market share, or obtain reimbursement from more third -partypayers and at higher prices than we do. We may not be able to compete effectively against these organizations. Increased competition and cost -savinginitiatives on the part of governmental entities and other third -partypayers are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. We also have limited intellectual property rights, which limits our ability to defend our market position or even enter certain markets. In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well -establishedand well -financedcompanies as use of next generation sequencing for clinical diagnosis and preventative care increases. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to website and systems development than we can. In the past, our competitors have been successful in recruiting our employees and may continue to recruit qualified employees from us. In addition, companies or governments that control access to genetic testing through umbrella contracts or regional preferences could promote our competitors or prevent us from performing certain services. Some of our competitors have obtained approval or clearance for certain of their tests from the relevant regulatory entities in the markets in which we expect to operate or the FDA. For example, if we decide to expand to the US market, and payers decide to reimburse only for tests that are FDA -approvedor FDA -cleared, or if they are more likely to reimburse for such tests, we may not be able to compete effectively unless we obtain similar approval or clearance for our tests. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance 30 and sales of our tests, which could prevent us from increasing our revenue or achieving profitability and could cause our share price to decline, all of which could have an adverse impact on our business, financial condition, results of operations and growth prospects. We may enter new business areas, such as additional services for the general population, primary care, and / or secondary care, which may include behavior modification and / or the adoption of new technologies, where we do not have any experience. If we were to enter new business areas, we would likely face competition from entities more familiar with those businesses, and our efforts may not succeed. In the future